Antileukotriene agents for the treatment of lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 5, 2013, Pages 538-544

  Scott, Jacob P ^a   Peters Golden, Marc ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Asthma; Leukotriene; Receptors; Slow reacting substance

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; SALMETEROL; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ALLERGIC RHINITIS; AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CHILDHOOD DISEASE; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; EXERCISE INDUCED BRONCHOSPASM; HEADACHE; HUMAN; INNATE IMMUNITY; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG DISEASE; MOOD CHANGE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SLEEP DISORDERED BREATHING; SUICIDAL IDEATION; SUICIDE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VASCULAR DISEASE;

ASTHMA; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG DISEASES;

EID: 84883522991     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201301-0023PP     Document Type: Review

References (89)

1. Brocklehurst WE. The release of histamine and formation of a slowreacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151:416-435.
2. Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta 2011;1810:1096-1102.
3. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357:1841-1854.
4. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009;124:406-414.
5. Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995;29:77-83.
6. Leigh R, Vethanayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, O'Byrne PM. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002;166:1212-1217.
7. Lazarus SC, Wong HH, Watts MJ, Boushey HA, Lavins BJ, Minkwitz MC. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997;156:1725-1730.
8. Terashima T, Amakawa K, Matsumaru A, Yamaguchi K. Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor. Chest 2002;122:1566-1570.
9. Dubé LM, Swanson LJ, Awni W. Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma: clinical pharmacokinetics and safety. Clin Rev Allergy Immunol 1999;17:213-221.
10. Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF, Bird SR, Edelman JM. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847-854.
11. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS; Exercise Study Group. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: A randomized, double-blind trial. Ann Intern Med 2000;132:97-104.
12. Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, Walton-Bowen K, LaVallee N, Stepanians M. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: A 3-month randomized controlled study. Ann Allergy Asthma Immunol 2007;99:178-184.
13. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-1066.
14. Spector SL, Smith LJ, GlassM; ACCOLATE Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-623.
15. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB; Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-1220.
16. Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006;130:1726-1732.
17. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, Seidenberg BC, Reiss TF; Montelukast/Beclomethasone Study Group. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial. Ann Intern Med 1999;130:487-495.
18. Cai C, Yang J, Hu S, Zhou M, Guo W. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007;185:105-112.
19. Rabinovitch N, Graber NJ, Chinchilli VM, Sorkness CA, Zeiger RS, Strunk RC, Bacharier LB, Martinez FD, Szefler SJ. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010;126:545-551.
20. Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, LumryWR, Picado C, Stevenson DD, Bousquet J, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
21. Kubavat AH, Khippal N, Tak S, Rijhwani P, Bhargava S, Patel T, Shah N, Kshatriya RR, Mittal R. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extendedrelease tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther 2013;20:154-162.
22. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695-1707.
23. Phipatanakul W, Greene C, Downes SJ, Cronin B, Eller TJ, Schneider LC, Irani AM. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91:49-54.
24. Ulrik CS, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clin Exp Allergy 2010;40:576-581.
25. Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, Angner R, Polis A, Dass SB, Lu S, et al.; Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003;21:123-128.
26. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, et al.; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-216.
27. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: A randomised double-blind placebo-controlled trial. Lancet 2001;357:2007-2011.
28. Löfdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, Seidenberg BC, Capizzi T, Kundu S, Godard P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999;319:87-90.
29. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K; Tokyo Joshi-Idai Asthma Research Group. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997;155:1235-1240.
30. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Dass SB, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protectingagainst asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891.
31. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-1095.
32. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting b2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011;5:CD003137.
33. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-1080.
34. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: A randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004;92:641-648.
35. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424-428.
36. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A; Pediatric Montelukast Study Group. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, doubleblind trial. JAMA 1998;279:1181-1186.
37. Barnes N, Thomas M, Price D, Tate H. The National Montelukast Survey. J Allergy Clin Immunol 2005;115:47-54.
38. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child 2010;95:365-370.
39. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC; CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012;367:904-912.
40. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, et al.; Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975-985.
41. Gentile DA, Fireman P, Skoner DP. Elevations of local leukotriene C4 levels during viral upper respiratory tract infections. Ann Allergy Asthma Immunol 2003;91:270-274.
42. Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167:379-383.
43. Kim CK, Choi J, Kim HB, Callaway Z, Shin BM, Kim JT, Fujisawa T, Koh YY. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010;156:749-754.
44. Amirav I, Luder AS, Kruger N, Borovitch Y, Babai I, Miron D, Zuker M, Tal G, Mandelberg A. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics 2008; 122:e1249-e1255.
45. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, Marchal JL, Dass SB, Reiss TF, Knorr BA. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008;178:854-860.
46. ProesmansM, Sauer K, Govaere E, RaesM, De Bilderling G, De Boeck K. Montelukast does not prevent reactive airway disease in young children hospitalized for RSV bronchiolitis. Acta Paediatr 2009;98:1830-1834.
47. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-322.
48. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-1029.
49. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotrienereceptor expression on nasal mucosal inflammatory cells in aspirinsensitive rhinosinusitis. N Engl J Med 2002;347:1493-1499.
50. Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157: 1187-1194.
51. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006;27:495-503.
52. Giouleka P, Papatheodorou G, Lyberopoulos P, Karakatsani A, Alchanatis M, Roussos C, Papiris S, Loukides S. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest 2011;41:30-38.
53. Fauler J, Frölich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997;27:43-47.
54. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, DeykinA, DiMangoE, Fish JE, Ford JG, et al.; NationalHeart Lung and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007;175:783-790.
55. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008;121:1365-1371.
56. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF; Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-1028.
57. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528-533.
58. Camargo CA Jr, Gurner DM, Smithline HA, Chapela R, Fabbri LM, Green SA, Malice MP, Legrand C, Dass SB, Knorr BA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010;125:374-380.
59. Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: A randomised, double-blind, placebocontrolled trial. Thorax 2011;66:7-11.
60. Zubairi AB, Salahuddin N, Khawaja A, Awan S, Shah AA, Haque AS, Husain SJ, Rao N, Khan JA. A randomized, double-blind, placebocontrolled trial of oral montelukast in acute asthma exacerbation. BMC Pulm Med 2013;13:20.
61. Heaton PC. Cost effectiveness of leukotriene modifiers in adults with asthma. Pharmacoeconomics 2006;24:727-742.
62. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002;20:909-918.
63. Menendez R, Stanford RH, Edwards L, Kalberg C, Rickard K. Cost- efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics 2001;19:865-874.
64. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-696.
65. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study. J Allergy Clin Immunol 2012;130:368-375.
66. Guilpain P, Viallard JF, Lagarde P, Cohen P, Kambouchner M, Pellegrin JL, Guillevin L. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002;41:535-539.
67. Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001;108:175-183.
68. Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: An analysis of the FDA AERS database. Thorax 2010;65:132-138.
69. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007;110:3263-3270.
70. National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management ofasthma-summary report 2007. J Allergy Clin Immunol 2007;120(5, Suppl):S94-S138.
71. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergeninduced airway responses. Am Rev Respir Dis 1993;147:839-844.
72. Wilborn J, Bailie M, Coffey M, Burdick M, Strieter R, Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996;97:1827-1836.
73. Kowal-Bielecka O, Distler O, Kowal K, Siergiejko Z, Chwiećko J, Sulik A, Gay RE, Łukaszyk AB, Gay S, Sierakowski S. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum 2003;48:1639-1646.
74. Lehtonen H, Oksa P, Lehtimäki L, Sepponen A, Nieminen R, Kankaanranta H, Saarelainen S, Järvenpää R, Uitti J, Moilanen E. Increased alveolar nitric oxide concentration and high levels of leukotriene B4 and 8- isoprostane in exhaled breath condensate in patients with asbestosis. Thorax 2007;62:602-607.
75. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-235.
76. Profita M, Giorgi RD, Sala A, Bonanno A, Riccobono L, Mirabella F, Gjomarkaj M, Bonsignore G, Bousquet J, Vignola AM. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005;60:1361-1369.
77. Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, Guntupalli KK, Jeffery PK. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 2012; 142:347-357.
78. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005;99:444-450.
79. Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, et al.; Copd Clinical Research Network. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 2011;8:21-29.
80. Stanke-Labesque F, Back M, Lefebvre B, Tamisier R, Baguet JP, Arnol N, Levy P, Pepin JL. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009;124:364-370.
81. Tsaoussoglou M, Lianou L, Maragozidis P, Hatzinikolaou S, Mavromati M, Orologas N, Panaghiotopoulou-Gartagani P, Rassidakis G, Balatsos NA, Chrousos G, et al. Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea. Sleep Med 2012;13:879-885.
82. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: A double-blind, placebo-controlled study. Pediatrics 2012;130:e575-e580.
83. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10: 181-193.
84. Riccioni G, Bäck M, Capra V. Leukotrienes and atherosclerosis. Curr Drug Targets 2010;11:882-887.
85. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998;157:219-229.
86. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian R, et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (In press).
87. Voelkel NF, Tuder RM, Wade K, Höper M, Lepley RA, Goulet JL, Koller BH, Fitzpatrick F. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 1996;97:2491-2498.
88. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005;174:589-594.
89. 4amplifies NF-kB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J Clin Invest 2011;121:671- 682.